Anzeige
Mehr »
Montag, 16.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
29 Leser
Artikel bewerten:
(0)

Global Over-the-Counter Drug Market 2016-2020 - Switching of Medications from Prescription to OTC / Counterfeit Drugs / Accelerated Use of Online Resources - Research and Markets

DUBLIN, August 22, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Over-the-Counter Drug Market 2016-2020" report to their offering.

The analysts forecast the global over-the-counter (OTC) drug market to grow at a CAGR of 6.19% during the period 2016-2020.

The report covers the present scenario and the growth prospects of the global over-the-counter (OTC) drug market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of OTC drugs used to treat disorders, including gastrointestinal disorders, pain, and dermatological and respiratory disorders.

OTC drugs are medicines that can be bought without a prescription from a doctor because the US FDA considers them safe for use without medical supervision. These drugs are used to treat conditions that do not necessarily require a doctor's advice, such as pain, itches, cough and cold, sleeping problems, smoking cessation, weight problems, gastrointestinal problems, and tooth decay. They are sold through hospitals, pharmaceutical stores, grocery stores, catalogs, and online retail stores.

Promotion and marketing initiatives will be a key trend for market growth. Vendors in this market are spending heavily on promotional activities targeted at both the healthy population and those with illnesses. They are trying to build a larger consumer base through marketing campaigns and activities through different media platforms. Marketing strategies for OTC products are very important, especially since these products lose the patent and enter the generic market, resulting in competition.

According to the report, one of the key drivers for market growth will be rise in self-medication. The growing healthcare costs and an increase in the older population demand the need for better accessibility and affordability of healthcare services. Self-medication with non-prescription drugs play an important role in this and help in improving the accessibility and cost-benefits of healthcare services. Apart from this, the increase in self-care and self-medication is influenced by factors such as lifestyle, socioeconomic factors, and easy accessibility of drugs.

Further, the report states that presence of counterfeit drugs will be a challenge for the market. The sale of counterfeit OTC drugs in the market is increasing, and this problem is usually unreported to the regulatory authorities in majority of the cases.

For instance, in April 2014, it was reported that over 2 million counterfeit drugs were seized from France, which included about 1 million packets of fake aspirin, which contained sugar in place of the API. It is estimated that counterfeit drugs account for 10% of the global market, as compared to 1% in the developed world, and the market for these drugs is on a rise. In the US, allergy OTC drugs are among the most counterfeited. Similarly, in 2015, over $100,000 worth fake medicines from the Philippines drugs market were seized.

Key vendors

- Bayer HealthCare

- GlaxoSmithKline (GSK)

- Johnson & Johnson

- Pfizer

- Sanofi

Key Topics Covered:

Part 01: Executive summary

Part 02: Scope of the report

Part 03: Market research methodology

Part 04: Introduction

Part 05: OTC drugs: An overview

Part 06: Market landscape

Part 07: Market segmentation by therapeutic class

Part 08: Global respiratory OTC drugs market

Part 09: Global dietary supplements market

Part 10: Global gastrointestinal OTC drugs market

Part 11: Global OTC pain medications market

Part 12: Market segmentation by route of administration

Part 13: Geographical segmentation

Part 14: Market drivers

Part 15: Impact of drivers

Part 16: Market challenges

Part 17: Impact of drivers and challenges

Part 18: Market trends

Part 19: Vendor landscape

Part 20: Key vendor analysis

For more information about this report visit http://www.researchandmarkets.com/research/85mrgd/global

Related Topics: Over the Counter (OTC) Drugs

Also Available

  • The OTC Drugs Market: Commercial Trends and Rx-to-OTC Switch Prospects
  • OTC Bulletin: The Business Newsletter for the Consumer Healthcare Industry

Media Contact:

Research and Markets

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

© 2016 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.